
If you're looking into GLP-1 treatment, you'll run into two kinds of products: FDA-approved brand-name medications, and compounded GLP-1s. They're often discussed as if they're the same thing at different prices. They aren't.
The differences come down to FDA approval, how the medication is prepared, how it's dosed, what it costs, and how much evidence sits behind the specific product you'd be taking. Here's what to understand before you start.
The Brand-Name Products
These are the ones you've heard of: semaglutide, sold as Wegovy, Ozempic, and now in oral forms; and tirzepatide, sold as Zepbound and Mounjaro.
Same active drug doesn't mean same approved use. One brand may be approved for type 2 diabetes while another with the same molecule is approved for weight management.
Before any of these reached the market, the FDA reviewed evidence on safety, effectiveness, manufacturing quality, dosing, and labeling. That doesn't make them risk-free — every medication has side effects. It means that specific product went through a formal review for that specific use.
What "Compounded" Actually Means
Compounding is a legitimate, long-standing part of U.S. healthcare. A compounded medication is prepared by a pharmacy or outsourcing facility, often to meet a particular patient's needs.
But compounded medications are not FDA-approved products. The FDA doesn't review each one for safety, effectiveness, or quality before it's dispensed.
That's why compounded semaglutide isn't "generic Ozempic," and compounded tirzepatide isn't "generic Zepbound." There are no generic versions of these drugs. The FDA has been actively warning companies against marketing compounded GLP-1s as identical or equivalent to approved products.


